Cenicriviroc, a dual chemokine receptor CCR5/CCR2 inhibitor, is under investigation because of its antiretroviral activity both in vitro and in vivo and its possible use in COVID-19 infections and nonalcoholic steatohepatitis (NASH) with fibrosis. Here, CCR5 is linked to metabolic dysfunction-associated steatohepatitis.